Neurointervention.  2012 Feb;7(1):23-26. 10.5469/neuroint.2012.7.1.23.

Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting

• Lee DH
• Kim HS
• Kim SM
• Kwon SU
• Suh DC

• KMID: 1783995
• DOI: http://doi.org/10.5469/neuroint.2012.7.1.23

Abstract

PURPOSE
VerifyNow antiplatelet assays were performed before and after stenting for various cerebral artery stenoses to determine the effect of the procedure itself to the function of dual antiplatelets given.
MATERIALS AND METHODS
A total of 30 consecutive patients underwent cerebral arterial stenting procedure were enrolled. The antiplatelet pretreatment regimen was aspirin (100 mg daily) and clopidogrel (300 mg of loading dose followed by 75mg daily). VerifyNow antiplatelet assay performed before and right after stenting. The two test results were compared in terms of aspirin-reaction unit (ARU), P2Y12 reaction units (PRU), baseline (BASE), and percentage inhibition. We evaluated occurrence of any intra-procedural in-stent thrombosis or immediate thromboembolic complication, and ischemic events in 1-month follow-up.
RESULTS
The median Pre-ARU was 418 (range, 350-586). For clopidogrel the medians of the pre-BASE, PRU, and percent inhibition were 338 (279-454), 256 (56-325), and 27% (0-57%). The medians of the post-ARU, BASE, PRU, and percent inhibition after stenting were 469 (range, 389-573), 378 (288-453), 274 (81-370), and 26% (0-79%). There was a significant increase of ARU (p=0.045), BASE (p=0.026), and PRU (p=0.018) before and after stenting. One immediate thromboembolic event was observed in poor-response group after stenting. There was no in-stent thrombosis and ischemic event in 1-month follow-up.
CONCLUSION
We observed a significant increase of platelet reactivity to dual antiplatelet therapy right after stenting procedure for various cerebral arterial stenoses.

Keyword

Stent; Cerebrovascular disorders; Atherosclerosis; Antiplatelet drugs; VerifyNow antiplatelet assay

MeSH Terms

Aspirin
Atherosclerosis
Blood Platelets
Cerebral Arteries
Cerebrovascular Disorders
Constriction, Pathologic
Humans
Platelet Aggregation Inhibitors
Stents
Thrombosis
Ticlopidine
Aspirin
Platelet Aggregation Inhibitors
Ticlopidine

Figure

• 

  Fig. 1 Individual changes of ARU (A) and PRU (B) values before and after the stenting procedures.

Reference

1. Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries (SSYLVIA): study results. Stroke. 2004; 35:1388–1392. PMID: 15105508.

2. Suh DC, Kim SJ, Lee DH, Kim W, Choi CG, Lee JH, et al. Outcome of endovascular treatment in symptomatic intracranial vascular stenosis. Korean J Radiol. 2005; 6:1–7. PMID: 15782013.

3. Fiorella D, Albuquerque FC, Woo H, Rasmussen PA, Masaryk TJ, McDougall CG. Neuroform in-stent stenosis: incidence, natural history, and treatment strategies. Neurosurgery. 2006; 59:34–42. PMID: 16823298.

4. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107:2908–2913. PMID: 12796140.

5. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: Consideration and management. J Interv Cardiol. 2006; 19:439–448. PMID: 17020569.

6. Lee DH, Arat A, Morsi H, Shaltoni H, Harris JR, Mawad ME. Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol. 2008; 29:1389–1394. PMID: 18483190.

7. Kang HS, Kwon BJ, Kim JE, Han MH. Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol. 2010; 31:1206–1210. PMID: 20223886.

8. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006; 28:315–322. PMID: 16845449.

9. Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, et al. The use of the VerifyNow-P2Y12 point-of-care device to monitor platelet function across a range of inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost. 2008; 99:409–415. PMID: 18278193.

10. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12 rapid analyzer: the verify thrombosis risk assessment (VERITAS) study. Thromb Res. 2007; 119:277–284. PMID: 16563469.

11. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost. 2007; 5:1839–1847. PMID: 17723123.

12. Jeong YH, Kim IS, Choi BR, Kwak CH, Hwang JY. The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow-P2Y12 assay. Eur Heart J. 2008; 29:2186–2187. PMID: 18617479.

13. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008; 29:992–1000. PMID: 18263931.

14. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol. 2008; 52:1128–1133. PMID: 18804738.

15. Gurbel PA, Tantry US. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 2006; 3:387–395. PMID: 16810174.

16. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51:1925–1934. PMID: 18482659.

17. Comin J, Kallmes D. Clopidogrel (plavix). AJNR Am J Neuroradiol. 2011; 32:2002–2004. PMID: 22135129.